Microbial biosensors to monitor the encapsulation effectiveness of Doxorubicin in chimeric advanced Drug Delivery Nano Systems: A calorimetric approach

详细信息    查看全文

• 作者：Konstantinos Gardikis^b ; Marco Signorelli^a ; Chiara Ferrario^a ; Alberto Schiraldi^a ; Maria Grazia Fortina^a ; Sophia Hatziantoniou^b ; Costas Demetzos^b ; Dimitrios Fessas^a ; ^{dimitrios.fessas@unimi.it}
• 关键词：chi-aDDnS ; chimeric advanced Drug Delivery nano-Systems ; ITC ; Isothermal Titration Calorimetry ; DOX ; doxorubicin ; Lactobacillus helveticus ; L. helveticus
• 刊名：International Journal of Pharmaceutics
• 出版年：2017
• 出版时间：10 January 2017
• 年：2017
• 卷：516
• 期：1-2
• 页码：178-184
• 全文大小：836 K
• 卷排序：516

文摘

The release of the anticancer drug doxorubicin (DOX) incorporated in a new drug carrier, namely a chimeric nanosystem formed by liposomes and dendrimers, was studied following the influence of the drug on the growth kinetics of the Lactobacillus helveticus bacterium, that would mimic the intestinal microflora.The bacterial growth was followed at 37 °C by means of Isothermal Titration Calorimetry (ITC) and the method was assessed to monitor the overall effect of the delivered drug obtaining simple objective parameters to define the encapsulation effectiveness of the system, discriminating dose effects even in cases of very low release. Traditional microbiological investigations and in vitro release tests were also performed in parallel for validation.The achieved results suggest that L. helveticus is an excellent candidate as biosensor to assess the sealing effectiveness of these DOX drug carriers through ITC investigations. This approach can be extended for quantitative comparison of drug delivery systems with the same drug inserted in other supramolecular bodies for quantitative comparison.The peculiar results for the DOX drug carrier system investigated, indicate also that, the use of hydrophilic dendrimers in this case, produce a high sealing effect that seems promising in terms of the intestinal flora protection.